Document:

EX-4.4

 Exhibit 4.4 
 PURSUANT TO THE TERMS OF SECTION 1 OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS
THAN THE AMOUNT SET FORTH ON THE FACE HEREOF. 
 CATALYST PHARMACEUTICAL PARTNERS, INC. 

WARRANT TO PURCHASE COMMON STOCK 
 Warrant No.: 2012 -
 Number of Shares of Common Stock:

Date of
Issuance:                         , 2012 (“Issuance Date”) 

Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged,                     , the registered holder hereof or its
permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Common Stock
(including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the Issuance Date (the “Exercisability Date”), but not after
11:59 p.m., New York time, on the Expiration Date (as defined
below),                             (           
 ) fully paid nonassessable shares of Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 17.
This Warrant is one of a series of Warrants to Purchase Common Stock (collectively, the “Warrants”) issued pursuant to that certain Underwriting Agreement, dated as
of                         , 2012 (the “Underwriting Date”), by and between the Company and Cowen and Company,
LLC, as representative of the several underwriters (the “Underwriting Agreement”) pursuant to the Company’s Registration Statement on Form S-1 (No. 333-180617) (as amended) (the “Registration Statement”).

 1. EXERCISE OF WARRANT.  
 (a) Mechanics of Exercise. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(e)), this Warrant may be exercised by the
Holder on any day on or after the Exercisability Date, in whole or in part (but not as to fractional shares), by (i) delivery of a written notice, which may be via e-mail provided that such notice is confirmed by the Company, in the form
attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant and (ii) if a registration statement registering the issuance of the Warrant Shares under the Securities Act of
1933, as amended (the “Securities Act”), is effective and available for the issuance of the Warrant Shares, or an exemption from registration under the Securities Act is available for the issuance of the Warrant Shares, payment to
the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash or wire transfer of immediately
available funds (a “Cash Exercise”) (the items under (i) and (ii) above, the “Exercise Delivery Documents”). The Holder shall not be required to surrender this Warrant in order to effect an exercise
hereunder; provided, however, that in the event that this Warrant is exercised in full or for the remaining unexercised portion hereof, the Holder shall deliver this Warrant to the Company for cancellation within a reasonable time after such
exercise. On or before the first Trading Day following the date on which the Company has received the Exercise Delivery Documents (the date upon which the Company has received all of the Exercise

 
Delivery Documents, the “Exercise Date”), the Company shall transmit by facsimile or e-mail transmission an acknowledgment of confirmation of receipt of the Exercise Delivery
Documents to the Holder and the Company’s transfer agent for the Common Stock (the “Transfer Agent”). The Company shall deliver any objection to the Exercise Delivery Documents on or before the second Trading Day following the
date on which the Company has received all of the Exercise Delivery Documents. On or before the third Trading Day following the date on which the Company has received all of the Exercise Delivery Documents (the “Share Delivery
Date”), the Company shall, (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program (the “FAST Program”) and so
long as the certificates therefor are not required to bear a legend regarding restriction on transferability, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such
exercise to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal At Custodian system, or (Y), if the Transfer Agent is not participating in the FAST Program or if the certificates are required to bear a
legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee,
for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the
Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case
may be. If this Warrant is submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired
upon an exercise, then the Company shall as soon as practicable and in no event later than five Trading Days after any such submission and at its own expense, issue a new Warrant (in accordance with Section 7(e)) representing the right to
purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant has been and/or is exercised. The Company shall pay any and all taxes and
other expenses of the Company (including overnight delivery charges) that may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant; provided, however, that the Company shall not be
required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder or an affiliate thereof. The Holder shall be responsible
for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. 
 (b) Exercise Price. For purposes of this Warrant, “Exercise Price” means $ per share of Common Stock, subject to adjustment as provided herein. 

(c) Company’s Failure to Timely Deliver Securities. In addition to any other rights available to a Holder, if the Company
fails to deliver to the Holder a certificate representing Warrant Shares by the third Trading Day after the Exercise Date, and if after such third Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three Trading Days after the Holder’s request and in
the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to deliver such certificate (and to issue such Common Stock) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such Common Stock and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Weighted Average Price of the Common Stock
on the Exercise Date. 

  
 2 

 (d) Cashless Exercise. Notwithstanding anything contained herein to the contrary, if
a registration statement registering the issuance of the Warrant Shares under the Securities Act is not effective or available for the issuance of the Warrant Shares, the Holder may, in its sole discretion, exercise this Warrant in whole or in part
and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common
Stock determined according to the following formula (a “Cashless Exercise”): 
 Net Number =
    (A x B) - (A x C)         

                    B 

For purposes of the foregoing formula: 
  

			
	 A=
	  	the total number of shares with respect to which this Warrant is then being exercised.
		
	 B=
	  	the Weighted Average Price of the shares of Common Stock (as reported by Bloomberg) on the date immediately preceding the date of the Exercise Notice.
		
	 C=
	  	the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

 (e) Rule 144. For purposes of Rule 144(d) promulgated under the Securities Act, as in effect on
the date hereof, assuming the Holder is not an affiliate of the Company, it is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be
deemed to have commenced, on the date this Warrant was originally issued pursuant to the Underwriting Agreement. 
 (f)
Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed.

 (g) Beneficial Ownership. The Company shall not effect the exercise of this Warrant, and the Holder shall not have the
right to exercise this Warrant, to the extent that after giving effect to such exercise, such Holder (together with such Holder’s affiliates and any other Persons acting as a group together) would beneficially own in excess of 9.99% (the
“Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise; provided, however, that this provision shall not apply to Holder’s who own more than the Maximum
Percentage prior to the Issuance Date. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon
exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant
beneficially owned by such Person and its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without
limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this
paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For purposes of this Warrant, in determining the number of
outstanding shares of Common Stock, the Holder may rely 

  
 3 

 
on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the
Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For
any reason at any time, upon the written or oral request of the Holder, the Company shall within two (2) Business Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock
was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% specified in such notice; provided that (i) any such increase
will not be effective until the sixty-first
(61st) day after such notice is delivered to the
Company, and (ii) any such increase or decrease will apply only to the Holder. The provisions of this Section 1(g) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 1(g) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. 
 (h) No Fractional Shares or Scrip. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price. 
 (i) Restrictions on Exercise. The Company shall
provide to the Holder prompt written notice of any time that the Company is unable to issue the Warrant Shares via DTC transfer (or otherwise without restrictive legend), because (A) the Commission has issued a stop order with respect to the
Registration Statement, (B) the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, (C) the Company has suspended or withdrawn the effectiveness of the
Registration Statement, either temporarily or permanently, or (D) the Registration Statement is otherwise not then effective (each a “Restrictive Legend Event”). To the extent that a Restrictive Legend Event occurs after the
Holder has exercised this Warrant but prior to the delivery of the Warrant Shares, the Company shall (i) if the Weighted Average Price over the last five consecutive trading days is greater than the Exercise Price, provide written notice to the
Holder that the Company will deliver that number of Warrant Shares to the Holder as should be delivered in a Cashless Exercise in accordance with Section 1(d), and return to the Holder all consideration paid to the Company in connection with
the Holder’s attempted exercise of this Warrant (a “Company-Elected Conversion”), or (ii) at the election of the Holder to be given within five (5) days of receipt of notice of a Company-Elected Conversion, the Holder
shall be entitled to rescind the previously submitted Exercise Notice and the Company shall return all consideration paid by Holder for such shares upon such rescission. The Company shall provide to the Holder prompt written notice of the
termination of the Restrictive Legend Event. The Holder understands that if the Company does not file reports pursuant to either Section 13(a) or Section 15(d) of the Exchange Act, or if a registration statement covering this Warrant or
the Warrant Shares, as applicable, is not in effect when it desires to sell (i) the rights to purchase Common Stock pursuant to this Warrant or (ii) the Common Stock issuable upon exercise of the right to purchase, the Holder may be
required to hold such securities for an indefinite period. The Holder also understands that any sale of (A) its rights hereunder to purchase Common Stock or (B) Common Stock issued or issuable hereunder that might be made by it in reliance
upon Rule 144 under the Securities Act may be made only in accordance with the terms and conditions of Rule 144. The Holder acknowledges and agrees that if a registration statement under the Securities Act covering the Warrant Shares is not
effective at the time this 

  
 4 

 
Warrant is exercised, the Holder shall only be permitted to exercise this Warrant by means of a Cashless Exercise pursuant to Section 1(d), in which case the Holder will receive a
certificate for the net Warrant Shares issuable under Section 1(d) containing a restrictive transfer legend. The Holder also acknowledges that the Company is not required to net cash settle this Warrant under any circumstances. 

2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be
adjusted from time to time as follows: 
 (a) Adjustment upon Subdivision or Combination of Common Stock. If the Company
at any time on or after the Underwriting Date subdivides (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of
shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Underwriting Date combines (by
any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to
such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(a) shall become effective at the close of business on the date the subdivision or
combination becomes effective. 
 (b) Other Events. If any event occurs of the type contemplated by the provisions of
this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features to the holders of the Company’s
equity securities), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this
Section 2(b) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2. 
 3. RIGHTS UPON DISTRIBUTION OF ASSETS. 
 (a) If the Company, at any time
while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holders) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security
other than the Common Stock (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of
which the denominator shall be the Weighted Average Price determined as of the record date mentioned above, and of which the numerator shall be such Weighted Average Price on such record date less the then per share fair market value at such record
date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors in good faith. In either case the adjustments shall be described in a
statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall
become effective immediately after the record date mentioned above. 
 4. PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.

 (a) Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if at any time the Company
grants, issues or sells any Options, Convertible Securities or rights to purchase 

  
 5 

 
stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of
Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Maximum
Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage, at which time the Holder shall be granted such right to the same extent as if there had been no
such limitation). 
 (b) Fundamental Transactions. The Company shall not enter into or be party to a Fundamental
Transaction unless the Successor Entity assumes in writing (unless the Company is the Successor Entity) all of the obligations of the Company under this Warrant in accordance with the provisions of this Section (4)(b). Upon the occurrence of any
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead
to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon
consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the
shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of the publicly traded common stock or common shares (or its equivalent) of the
Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been exercised immediately prior to such Fundamental Transaction, as adjusted in
accordance with the provisions of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to
receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive
upon an exercise of this Warrant at any time after the consummation of the Corporate Event but prior to the Expiration Date, in lieu of shares of Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of
this Warrant prior to such Corporate Event, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the
happening of such Corporate Event had this Warrant been exercised immediately prior to such Corporate Event and shall be applied without regard to any limitations on the exercise of this Warrant. Provision made pursuant to the preceding sentence
shall be in a form and substance reasonably satisfactory to the Required Holders. The provisions of this Section 4(b) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied
without regard to any limitations on the exercise of this Warrant. 
 (c) Applicability to Successive Transactions. The
provisions of this Section 4 shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant. 

  
 6 

 5. RESERVATION OF WARRANT SHARES. The Company covenants that it will at all times
reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of
shares of Common Stock which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive or any other contingent purchase rights of Persons other than the Holder (taking into account the adjustments and
restrictions in Section 2). Such reservation shall comply with the provisions of Section 1. The Company covenants that all shares of Common Stock so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise
Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such actions as may be necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. 

6. WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such
Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon
the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then
entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. 
 7.
REGISTRATION AND REISSUANCE OF WARRANTS. 
 (a) Registration of Warrant. The Company shall register this Warrant,
upon the records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall also register any transfer, exchange, reissuance or cancellation of
any portion of this Warrant in the Warrant Register. 
 (b) Transfer of Warrant. This Warrant may be offered for sale,
sold, transferred or assigned without the consent of the Company, except as may otherwise be required by applicable securities laws. Subject to applicable securities laws, if this Warrant is to be transferred, the Holder shall surrender this Warrant
to the Company and deliver the completed and executed Assignment Form, in the form attached hereto as Exhibit B, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with
Section 7(e)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less then the total number of Warrant Shares then underlying this Warrant is
being transferred, a new Warrant (in accordance with Section 7(e)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. 

(c) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of
this Warrant, the 

  
 7 

 
Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(e)) representing the right to purchase the Warrant Shares then underlying this Warrant.

 (d) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the
principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(e)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant
will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given. 

(e) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such
new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being
issued pursuant to Section 7(b) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance,
does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and
conditions as this Warrant. 
 8. NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise
provided herein, such notice shall be given in accordance with the information set forth in the Warrant Register. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including, in reasonable
detail, a description of such action and the reason or reasons therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) promptly upon any adjustment of the Exercise Price, setting forth
in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares
of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock
or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided, that in each case, such information shall be made known to the public prior to or in conjunction with such notice
being provided to the Holder. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in writing, will be mailed (a) if within the domestic United States by first-class registered
or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile or (b) if delivered from outside the United States, by International Federal Express or facsimile, and (c) will be deemed given
(i) if delivered by first-class registered or certified mail domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by
International Federal Express, two business days after so mailed and (iv) if delivered by facsimile, upon electronic confirmation of receipt, and will be delivered and addressed as follows: 

(i) if to the Company, to: 
 Catalyst Pharmaceutical Partners, Inc. 
 355 Alhambra Circle, Suite
1500 
 Coral Gables, Florida 33134 

Telecopy number: (305) 529-0933 

Attention: Patrick J. McEnany, Chairman, President and Chief Executive Officer 

  
 8 

 with a copy (which shall not constitute notice) to: 

Akerman Senterfitt 
 One Southeast Third Avenue, Suite 2500 
 Miami, Florida 33131

 Telecopy number: (305) 349-4833 

Attention: Philip B. Schwartz 
 (ii) if to the Holder, at the address of the Holder appearing in the Warrant Register. 
 9. NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation, Bylaws or through any reorganization, transfer of assets,
consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith
comply with all the provisions of this Warrant and take all actions consistent with effectuating the purposes of this Warrant. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of
Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as this Warrant is outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock,
solely for the purpose of effecting the exercise of this Warrant, 100% of the number of shares of Common Stock issuable upon exercise of this Warrant then outstanding (without regard to any limitations on exercise). 

10. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant (other than Section 1(g)) may
be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. No consideration shall be offered or paid to the
Holder to amend or consent to a waiver or modification of any provision of this Warrant unless the same consideration is also offered to all of the holders of the other Warrants. No waiver shall be effective unless it is in writing and signed by an
authorized representative of the waiving party. 
 11. GOVERNING LAW. This Warrant shall be governed by and construed and
enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. 

12. HEADINGS. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the
interpretation of, this Warrant. 
 13. DISPUTE RESOLUTION. In the case of a dispute as to the determination of the
Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the Exercise Notice giving rise to such
dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic
calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected

  
 9 

 
by the Company and approved by the Holder, which approval shall not be unreasonably withheld, or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s
independent, outside accountant. The Company shall cause the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days
from the time it receives the disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error. The expenses of
the investment bank and accountant will be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares by the Holder was incorrect, in
which case the expenses of the investment bank and accountant will be borne by the Holder. 
 14. REMEDIES, OTHER
OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the Underwriting Agreement, at law or in equity (including a decree of
specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by
it of its obligations hereunder may cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this
Warrant shall be entitled, in addition to all other available remedies, to seek an injunction restraining any breach. Notwithstanding the foregoing or anything else herein or in the Underwriting Agreement to the contrary, other than as expressly
provided in Section 1(c), if the Company is for any reason unable to issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to pay to the Holder any cash or
other consideration or otherwise “net cash settle” this Warrant. 
 15. LIMITATION ON LIABILITY. No provisions
hereof, in the absence of affirmative action by the Holder to purchase Warrant Shares hereunder, shall give rise to any liability of the Holder to pay the Exercise Price or as a shareholder of the Company (whether such liability is asserted by the
Company or creditors of the Company). 
 16. SUCCESSORS AND ASSIGNS. This Warrant shall bind and inure to the benefit of
and be enforceable by the Company and the Holder and their respective permitted successors and assigns. 
 17. CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings: 
 (a)
“Bloomberg” means Bloomberg L.P. 
 (b) “Business Day” means any day other than Saturday,
Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. 
 (c)
“Common Stock” means (i) the Company’s shares of Common Stock, par value $0.001 per share, and (ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a
reclassification of such Common Stock. 
 (d) “Convertible Securities” means any stock or securities (other
than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock. 
 (e)
“Eligible Market” means the Principal Market, The New York Stock Exchange, Inc., The NYSE Amex, The NASDAQ Global Market or The NASDAQ Global Select Market. 

  
 10 

 (f) “Expiration Date” means the fifth anniversary of the Exercisability
Date or, if such date falls on a day other than a Trading Day or on which trading does not take place on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities
exchange or securities market on which the Common Stock is then traded (a “Holiday”), the next date that is not a Holiday. 
 (g) “Fundamental Transaction” means that (a) the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or
not the Company is the surviving corporation) another Person (but excluding a migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company), (ii) sell, assign, transfer, convey or otherwise
dispose of all or substantially all of the properties or assets of the Company to another Person, (iii) allow another Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares
of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), (iv) consummate a stock
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of
Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination),
or (v) reorganize, recapitalize or reclassify its Common Stock, or (b) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock. 

(h) “Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible
Securities. 
 (i) “Parent Entity” of a Person means an entity that, directly or indirectly, controls the
applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization
as of the date of consummation of the Fundamental Transaction. 
 (j) “Person” means an individual, a limited
liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. 

(k) “Principal Market” means The NASDAQ Capital Market. 

(l) “Required Holders” as of any time means the holders of the Warrants representing at least a majority of shares of
Common Stock underlying the Warrants then outstanding. 
 (m) “Successor Entity” means the Person (or, if so
elected by the Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered
into. 
 (n) “Trading Day” means any day on which the Common Stock is traded on the Principal Market, or, if
the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; 

  
 11 

 
provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the
Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at
4:00:00 p.m., New York time). 
 (o) “Weighted Average Price” means, for any security as of any date, the
dollar volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at
4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar
volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly
announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted
average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets” by OTC
Markets LLC. If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the
Company and the Required Holders. If the Company and the Required Holders are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 13 with the term “Weighted Average
Price” being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation
period. 

  
 12 

 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to
be duly executed as of the Issuance Date set out above. 
  

			
	CATALYST PHARMACEUTICAL PARTNERS, INC.
		
	By:	 	 
	Name:	 	Patrick J. McEnany
	Title:	 	Chairman, President and Chief Executive Officer

  

 EXHIBIT A 

EXERCISE NOTICE 
 TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS WARRANT TO PURCHASE COMMON STOCK 
 CATALYST PHARMACEUTICAL PARTNERS, INC. 
 The undersigned holder hereby
exercises the right to purchase                  of the shares of Common Stock (“Warrant Shares”) of Catalyst Pharmaceutical Partners, Inc., a Delaware
corporation (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the
Warrant. 
 1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):

             a “Cash Exercise” with
respect to                  Warrant Shares; and/or 
             a “Cashless Exercise” with respect to
                 Warrant Shares in accordance with and if permitted under Section 1(d) of the Warrant. 

2. Payment of Exercise Price. Unless the Holder has elected a Cashless Exercise with respect to some or all of the Warrant Shares
to be issued pursuant hereto in accordance with and if permitted by Section 1(d), the holder shall pay the Aggregate Exercise Price in the sum of
$                 to the Company in accordance with the terms of the Warrant. 
 3. Delivery of Warrant Shares. The Company shall deliver to the holder                  Warrant Shares in accordance
with the terms of the Warrant and, after delivery of such Warrant Shares,                  Warrant Shares remain subject to the Warrant. 

Date:             ,             

  
  
 Name of Registered Holder 
  
  

			
	
		
	By:	 	 
	Name:	 	
	Title:	 	

 EXHIBIT B 

ASSIGNMENT FORM 
 CATALYST PHARMACEUTICAL PARTNERS, INC. (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)  

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 

 

					
	 Name:
	  	  
	  	
		  	(Please Print)	  	
			
	 Address:
	  	  
	  	
			
		  	  
	  	
			
		  	  
	  	
			
		  	  
	  	

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Stock Purchase Warrant

 Exhibit 4.1 
 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH
SALE OR TRANSFER IS IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS IS AVAILABLE WITH RESPECT THERETO. 

STOCK PURCHASE WARRANT 
 Warrant
No. W-001 
 CYBEX INTERNATIONAL, INC. 
 Issued on March 15, 2012 
 Void after March 15, 2022

 1. Issuance. This Stock Purchase Warrant (the “Warrant”) is issued to RBS CITIZENS,
N.A. (“Citizens” and, together with its successors and assigns, hereinafter called “Holder”) by CYBEX INTERNATIONAL, INC. a New York corporation (hereinafter with its successors and
assigns called the “Company”). This Warrant is being issued in connection with, and as additional consideration for Citizens’ agreements in, that certain Loan Modification Agreement of even date herewith among Citizens, the
Company and Cybex International UK Limited, which Loan Modification Agreement amends and modifies certain of the Loan Documents (as defined therein) (such Loan Documents, as amended by such Loan Modification Agreement and as further amended and/or
restated and in effect from time to time, collectively, the “Loan Agreement”). Accordingly, the Company acknowledges and agrees hereby that all consideration required for the Company to issue this Warrant has been received by the
Company from Holder as of the date of issuance. 
 2. Class; Exercise Price; Number of Shares. 

Commencing on the date hereof, Holder is entitled upon surrender of this Warrant with the subscription form annexed hereto duly executed,
at the principal office of the Company, to purchase from the Company, up to such seventy-five thousand (75,000) shares (the “Shares”) of the Company’s common stock, $0.10 par value per share (hereinafter “Common
Stock” or, as adjusted from time to time hereunder, the “Class”) at a purchase per Share equal to $0.10 (the “Exercise Price”). 
 Until such time as this Warrant is exercised in full or expires, the Exercise Price, the Class and the number of Shares issuable upon exercise of this Warrant are subject to adjustment as hereinafter
provided. The person or persons in whose name or names any certificate representing Shares issued upon any exercise hereof shall be deemed to have become the holder of record of such Shares as at the close of business on the date this Warrant is
exercised with respect to such Shares, whether or not the transfer books of the Company shall be closed. 
 3. Payment of
Exercise Price. Subject to Section 4 below, the aggregate Exercise Price may be paid (i) in cash or by check, (ii) by the surrender by the Holder to the Company of any promissory notes or other obligations issued by the Company,
with all such notes and obligations so surrendered being credited against the aggregate Exercise Price in an amount equal to the principal amount thereof plus accrued interest to the date of surrender, or (iii) by any combination of the
foregoing. 

 4. Net Issue Election. In lieu of payment of the aggregate Exercise Price in
accordance with Section 3 above, the Holder may elect to receive Shares equal to the value of this Warrant or any portion hereof by the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto
duly executed, at the principal office of the Company. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

 

					
		 	X=  Y(A-B)	 	
		 	    A	 	

  

					
	where:	  	X =	  	the number of Shares to be issued to the Holder pursuant to this Section 4.
			
		  	Y =	  	the number of Shares covered by this Warrant in respect of which the net issue election is made pursuant to this Section 4 (including, without limitation, the Shares
surrendered to the Company in payment of the aggregate Exercise Price).
			
		  	A =	  	the Fair Market Value (defined below) of one Share, as determined at the time the net issue election is made pursuant to this Section 4.
			
		  	B =	  	the Exercise Price in effect at the time the net issue election is made pursuant to this Section 4.

 “Fair Market Value” of a Share as of the date that the net issue election is made (the
“Determination Date”) shall mean: 
 (i) If shares of the Class are then traded on a securities
exchange or the Nasdaq National Market, the fair market value of a Share shall be the average of the closing or last reported sale prices of a share of the Class on such exchange or market over the five (5) consecutive trading days period
ending five (5) trading days prior to the Determination Date (or, if the Company’s Common Stock is then so traded and the Class is a series of convertible preferred stock, the fair market value of a Share shall equal such 5-day average for
the Common Stock multiplied by the number of shares of Common Stock for which a Share is then convertible); 
 (ii) If
shares of the Class are otherwise traded in an over-the-counter market, the fair market value of a Share shall be the average of the closing ask prices for a share of the Class over the five (5) consecutive trading day period ending five
(5) trading days prior to the Determination Date (or, if the Company’s Common Stock is then so traded and the Class is a series of convertible preferred stock, the fair market value of a Share shall equal such 5-day average for the Common
Stock multiplied by the number of shares of Common Stock for which a Share is then convertible); or 
 (iii) If at the
Determination Date there is no public market for shares of the Class or Common Stock, then the fair market value of a share of the Class shall be determined in accordance with the procedures set forth in Section 14(c)(ii) below.

 5. Partial Exercise. This Warrant may be exercised in part, and the Holder shall be entitled to receive a new warrant
of like tenor, which shall be dated as of the date of this Warrant, representing the Shares not so purchased upon such exercise. 
 6. Fractional Shares. No fractional Share shall be issued upon any exercise of this Warrant. If, upon exercise of this Warrant in its entirety, the Holder would be entitled to receive a fractional
Share, then the Company shall, in lieu of such fractional Share, pay to Holder in cash an amount equal to the Fair Market Value (as defined in Section 4 above) of such fractional Share. 

7. Expiration Date; Treatment of Warrant on Acquisition. 

(a) Expiration Date. This Warrant shall expire on the earlier to occur of (i) 5:00 PM, US
Eastern time, on the tenth (10th) anniversary of the
original issue date hereof (or, if such date be not a business day, then at 5:00 PM, US Eastern time on the first business day following such date), or (ii) the closing of a Qualified Acquisition. 

  
 -2-

 (b) Treatment of Warrant on Acquisition. 

(1) Certain Definitions. As used herein: 
 “Acquisition” means (i) a sale, assignment, transfer or other disposition of all or substantially all of the Company’s assets to an Unaffiliated Entity (as defined below)
(“Asset Sale”), (ii) a merger or consolidation of the Company into or with an Unaffiliated Entity where the Company is not the surviving entity (other than a merger the sole purpose of which is to change the Company’s
domicile), (iii) any transaction or series of related transactions pursuant to which Company stockholders sell or otherwise transfer outstanding Company shares constituting a majority of the total outstanding combined voting power of the
Company to an Unaffiliated Entity, or (iv) upon the closing of a Going Private Transaction. 
 “Going Private
Transaction” means a Rule 13e-3 transaction (as defined in the Exchange Act) with respect to the Company as issuer. 

“Qualified Acquisition” means an Acquisition in which the sole consideration received by the Company and/or its
stockholders (as applicable) consists of cash and/or Marketable Securities. 
 “Unaffiliated Entity” means any
entity that is owned or controlled by parties who own less than twenty percent (20%) of the combined voting power of the voting securities of the Company immediately prior to the Acquisition. 

“Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then
subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information
under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof
is then actively traded on a national securities exchange or over-the-counter market, and (iii) Holder would not be restricted by contract or by applicable federal and state securities laws from publicly re-selling, within six (6) months
and one (1) day following the closing of such Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of
such Acquisition. 
 (2) Treatment of Warrant. This Warrant shall terminate on the closing of any Qualified Acquisition
to the extent not exercised prior thereto (which exercise may be made conditional upon the closing of such Qualified Acquisition); provided, that in the case of a Qualified Acquisition that is an Asset Sale, this Warrant shall continue until
the Company makes a liquidating distribution to its stockholders of the net proceeds therefrom. In connection with any Acquisition other than a Qualified Acquisition, the Company shall, and hereby agrees to, cause the acquiror to assume this Warrant
on and as of the closing thereof, and thereafter this Warrant shall be exercisable for the same securities and other property as would have been received by Holder in respect of the Shares had this Warrant been exercised in full as of immediately
prior to such closing in accordance with Section 3 above, for the same aggregate Exercise Price as in effect as of immediately prior to such closing, subject to adjustment thereafter from time to time in accordance with the provisions of
this Warrant. 
 (3) Notice of Acquisition. The Company shall provide Holder with written notice of any Acquisition not
less than ten (10) days prior to the closing thereof (which notice shall summarize the principal terms and conditions of such Acquisition), and shall provide Holder at its request with copies of all term sheets, draft and definitive transaction
agreements and documents and other information and materials respecting such Acquisition as Holder may reasonably request, promptly following Holder’s request therefor. 
 8. Reserved Shares; Valid Issuance. The Company covenants that it will at all times from and after the date hereof reserve and keep available out of its authorized and unissued capital stock such
number of shares as will be sufficient to permit the exercise of this Warrant in full and, if applicable, the conversion of the Shares issuable upon such exercise into shares of Common Stock. The Company further covenants that all Shares issued
pursuant to such exercise and, if applicable, such conversion will, upon issuance, be duly and validly issued, fully paid and non-assessable and free from all taxes, liens, charges, claims and encumbrances (other than restrictions imposed by
applicable federal and state securities laws). 

  
 -3-

 9. Stock Splits and Dividends. If after the date thereof the Company shall subdivide
the Shares, by split-up or otherwise, or combine the Shares, or issue additional shares of the Shares in payment of a stock dividend, then number of shares of the Shares issuable on the exercise of this Warrant shall forthwith be proportionately
increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Exercise Price shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or
proportionately increased in the case of a combination. 
 10. Reclassifications Etc. If after the date thereof there
shall be any reclassification, reorganization, recapitalization, substitution, exchange or like event affecting the outstanding shares of the Class (other than an event described in Section 9 above), this Warrant shall, following such
event, be exercisable for the same class, series and number of securities and other property that Holder would have received had Holder exercised this Warrant in full in accordance with Section 3 above as of immediately prior to the
effectiveness of such event, and the Exercise Price shall be adjusted proportionately. 
 11. Certificate of Adjustment.
Whenever the Class, Exercise Price or number of Shares is adjusted, as herein provided, the Company shall promptly deliver to the Holder a certificate of the Company’s chief financial officer or treasurer setting forth the Exercise Price after
such adjustment and setting forth a brief statement of the facts requiring such adjustment. 
 12. Notice of Certain
Events. If the Company proposes at any time (a) to declare, make or pay any dividend or distribution upon the outstanding shares of the Class, whether in cash, securities or other property and whether or not a regular cash dividend, or to
repurchase or redeem any outstanding shares of the Class from any holder or holders thereof; (b) to offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of
the Company’s stock; (c) to effect any reclassification, reorganization, recapitalization, substitution, exchange or like event affecting the outstanding shares of the Class; or (d) to effect an Acquisition or to liquidate, dissolve
or wind up; then, in connection with each such event, the Company shall give Holder (x) if the Company is then subject to the reporting requirements of the Exchange Act, notice of such event at the same time and in the same manner as given by
the Company to the holders of the outstanding shares of the Class; or (y) if the Company is not then subject to the reporting requirements the Exchange Act, at least ten (10) days written notice thereof prior to the earliest to occur of
(i) any record date for determining the stockholders entitled to vote thereon, (ii) any vote of stockholders thereon (whether at a meeting or by written consent in lieu of meeting), or (iii) the consummation or effective date thereof.

 13. [Intentionally Omitted]. 
 14. Holder Put Right. The rights and obligations set forth in this Section 14 shall only apply at all times, if any, when the Company shall not be subject to the reporting requirements of the
Exchange Act. 
 (a) At any time on or after the earlier to occur of (i) a Trigger Event (as defined below), or
(ii) the second (2d) anniversary of the original issue date of this Warrant, Holder shall have the right (but not the obligation), exercisable upon not less than twenty (20) days prior written notice to the Company (the “Put
Notice”), to require the Company to repurchase this Warrant (together with all (but not less than all) Shares issued on any and all prior exercises hereof), and the Company hereby agrees to repurchase this Warrant together with such Shares
(if any) in accordance with the requirements of this Section 14. The purchase price to the Company (the “Put Price”) shall equal (x)(1) the Share Value (as defined below), less (2) the then-effective Exercise Price,
multiplied by (y) the total number of Shares for which this Warrant is then exercisable (and, if Shares issued upon one or more prior exercises are being repurchased, the Share Value multiplied by the total number of such Shares). 

(b) The closing of the sale and purchase of this Warrant (and the Shares, if any) pursuant to Holder’s exercise of its rights
under this Section 14 (the “Put Closing”) shall occur at the principal office of Holder at 10:00 AM, local time, on the later of (i) the date that is twenty (20) days from the date of the Put Notice, or
(ii) ten (10) days following determination of the Share Value in accordance with Section 14(c)(ii) below), or at such other place, time and/or date as the parties may agree upon in writing. At the Put Closing, the Company shall
deliver payment of the Put Price to Holder in cash, in immediately available funds, in a single installment, by certified or bank cashier’s check or by wire transfer of funds to Holder’s designated account, against receipt from Holder of
the original of this Warrant (and, if applicable, the certificate(s) evidencing the Shares issued on all previous exercises hereof), duly endorsed by Holder for transfer on the books of the Company or accompanied by duly executed stock powers or
other transfer instruments. 

  
 -4-

 (c) As used herein: 

(i) “Trigger Event” means any of the following: (1) an Event of Default under, and as defined in, the Loan
Agreement, or (2) from and after the date (if any) that the Company shall have repaid in full all Obligations under, and as defined in, the Loan Agreement and the Loan Agreement shall have terminated, a default by the Company under, or a breach
by the Company of, any material agreement, contract, lease, license, mortgage, indenture or deed of trust to which the Company is then a party or is subject or by which the Company may be bound. 

(ii) “Share Value” means the fair market value of a Share determined as of the date of the Put
Notice), as follows. The Company shall within five (5) business days following receipt of the Put Notice provide to Holder in writing a statement (the “Value Statement”) of the then-fair market value of a Share as determined in
good faith by the Company’s Board of Directors, which written statement shall describe the method by which the Board of Directors determined such fair market value. Holder shall have a period of twenty (20) days following its receipt of
the Value Statement in which to agree in writing with the Company as to the Share Value. If the Company and Holder shall not have agreed in writing on the Share Value within such 20-day period, then the Share Value shall be determined by third party
appraisal as follows: each of the Company and Holder shall choose one appraiser, and a third appraiser shall be chosen by agreement of the appraisers chosen by the Company and Holder, provide that each such appraiser shall be a person or firm of
good reputation with experience in valuing companies of similar size to, and in the same business or industry as, the Company. The value given by each such appraiser shall be determined without any discounts on account of illiquidity or minority
ownership. The Share Value shall be the average of the values given by the three appraisers, and such Share Value shall be conclusive for all purposes of this Warrant. Each of the Company and Holder shall bear the respective fees, costs and expenses
of the appraiser selected by it, and 50% of the fees, costs and expenses of the third appraiser; provided, that if the final Share Value as determined pursuant to the foregoing appraisal process exceeds the value given by the Company in the value
Statement by ten percent (10%) or more, then all fees, costs and expenses of all three appraisers shall be borne and paid solely by the Company. Such appraisal process shall be commenced as soon as reasonably practicable following the
expiration of such 20-day period and completed within thirty (30) days following commencement, but in all events completed no later than the sixtieth (60th) day following expiration of such 20-day period. The Company agrees to reasonably cooperate with each appraiser
at all times and to provide such appraiser with all reasonable access to Company premises and personnel and with copies of all Company financial, business and other information and materials reasonably requested by such appraiser promptly following
its request therefor. Notwithstanding the foregoing provisions of this Section 14(c)(ii), if the put right of Holder under Section 14(a) or the call right of the Company under Section 15(a) is exercised in
connection with an Acquisition, then the Share Value shall equal the value of the consideration per Share (as determined in accordance with the definitive executed transaction documents for such Acquisition) that Holder would receive were Holder to
exercise this Warrant prior to the closing of such Acquisition. 
 (d) The put right of Holder set forth in this
Section 14 shall terminate and be of no further force or effect following the closing of an Acquisition. 
 15.
[Intentionally Omitted] 
 16. Drag-Along Right; Tag-Along Right. The rights and obligations set forth in this
Section 16 shall only apply at all times, if any, when the Company shall not be subject to the reporting requirements of the Exchange Act. 
 (a) Drag-Along Right. 
 (i) Subject to the provisions of
Section 7(b) above (which shall control in the event of any conflict or inconsistency with the provisions of this Section 16(a)), in the event that one or more persons holding shares of Company capital stock representing not
less than a majority of the then total issued and outstanding shares of Common Stock, calculated on a fully-diluted basis (the “Dragging Holders”), desire to effect an Acquisition, then Holder shall be obligated to and shall upon
the written request of the Dragging Holders, (1) if the Acquisition involves the sale of outstanding shares, sell, transfer and deliver, or cause to be sold, transferred and delivered, to the third party acquiror a pro rata portion of the
shares to be sold, based on the total number of outstanding Shares issued and issuable hereunder and held by Holder, on substantially the same terms and conditions applicable to the Dragging Holders; and (2) execute and deliver such instruments
of conveyance and 

  
 -5-

 
transfer and take all reasonably necessary actions, including voting such Shares as may then be outstanding in favor of any Acquisition proposed by the Dragging Holders and executing any purchase
agreements, merger agreements, voting agreements, support agreements, indemnity agreements, escrow agreements or related documents, that such Dragging Holders or the third party acquiror may reasonably require in order to carry out the terms and
provisions of this Section 16(a) (the “Drag Along Right”). 
 (ii) Not less than ten
(10) days prior to the date proposed for the closing of any Acquisition, the Dragging Holders shall give written notice to Holder, setting forth in reasonable detail the name or names of the third-party acquiror, and the material terms and
conditions of the Acquisition, including the transaction price, and the proposed closing date. 
 (b) Tag-Along
Right. If at any time any one or more holders or beneficial owners (individually or collectively, “Selling Holder”) of outstanding shares of Company capital stock or of securities or instruments convertible into or exercisable
for shares of Company capital stock (“Securities”) desire or propose to sell, assign or otherwise transfer (“Transfer”), in a bona fide private single transaction or series of related transactions, Securities
representing twenty percent (20%) or more of the total issued and outstanding capital stock of the Company (calculated on a fully-diluted basis) (the “Proposed Sale Transaction”) to any person or entity (a “Proposed
Transferee”), the Company shall cause such Selling Holder to comply with, and shall not consent to such Transfer by such Selling Holder unless such Selling Holder shall have complied with, the following provisions of this
Section 16(b): 
 (i) No later than twenty (20) business days prior to the consummation of the Proposed Sale
Transaction, the Selling Holder shall provide Holder notice of the Proposed Sale Transaction (the “Tag Along Notice”) and of Holder’s right to participate in the Proposed Sale Transaction on a pro rata basis with the Selling
Holder as calculated pursuant to Section 16(b)(iii)) below; provided that Holder shall not be entitled to sell more than the number of Shares described in Section 16(b)(iii) (the “Tag Along Right”). The Tag Along
Notice shall identify the Proposed Transferee and all material terms, conditions and information of and in connection with the Proposed Sale Transaction. 
 (ii) Holder shall have the right to exercise its Tag Along Right by giving written notice of such intent to participate (the “Tag Along Acceptance Notice”) to the Selling Holder within
ten (10) days after receipt by Holder of the Tag Along Notice (the “Tag Along Election Period”). Each Tag Along Acceptance Notice shall indicate the maximum number of Shares Holder wishes to sell. The delivery of the Tag Along
Acceptance Notice shall constitute an irrevocable offer by Holder to sell the Shares indicated therein for the price and on the terms and conditions described in the Tag Along Notice and such other terms and conditions applicable to the Selling
Holder and otherwise in accordance with this Section 16(b); provided that Holder shall not be entitled to sell more than the number of Shares described in Section 16(b)(iii). If the Class is a series of convertible preferred
stock, Holder shall be permitted to sell to the relevant Proposed Transferee in connection with any exercise of the Tag Along Right, at its option, (1) shares of Common Stock acquired upon conversion of such convertible preferred stock, or
(2) shares of convertible preferred stock. 
 (iii) Holder shall have the right to sell in the Proposed Sale Transaction a
portion of its Shares which is equal to or less than the product obtained by multiplying the total number of Securities proposed to be sold to the Proposed Transferee in the Proposed Sale Transaction by a fraction, the numerator of which is the
total number of Shares for which this Warrant is then exercisable together with all Shares issued to Holder (and still then owned by Holder) upon all prior exercises hereof, and the denominator of which is the total number of Securities held by
Holder and Selling Holder, in each case as of the date of the Tag Along Notice. 
 (iv) Within ten (10) calendar days
after the end of the Tag Along Election Period, the Selling Holder shall promptly notify Holder of the number of Shares held by Holder that will be included in the sale and the date on which the Proposed Sale Transaction will be consummated, which
shall be no later than the later of (1) thirty (30) calendar days after the end of the Tag Along Election Period and (2) the satisfaction of any governmental approval or filing requirements, if any. Holder may effect its participation
in any Proposed Sale Transaction hereunder by (1) execution and delivery to the Proposed Transferee, or to the Selling Holder for delivery to the Proposed Transferee, of one or more instruments of conveyance and transfer or certificates,
properly endorsed for transfer, representing the Shares to be sold by it and (2) executing any purchase agreements, indemnity agreements, escrow agreements or related documents that the Selling Holder is executing. At the time of consummation
of the Proposed Sale Transaction, the Proposed Transferee shall remit directly to Holder that portion 

  
 -6-

 
of the sale proceeds to which Holder is entitled by reason of its participation with respect thereto (less Holder’s pro rata share (based on its Shares being sold) of any sale proceeds to be
escrowed or held back). No Securities may be purchased by the Proposed Transferee from the Selling Holder unless the Proposed Transferee simultaneously purchases from Holder all of the Shares that it have elected and is entitled to sell pursuant to
this Section 16(b). 
 (v) Any Securities held by a Selling Holder that are the subject of the Proposed Sale
Transaction and that the Selling Holder desires to Transfer following compliance with this Section 16(b), may be sold to the Proposed Transferee only during the period specified in Section 16(b)(iv) and only on terms no more
favorable to the Selling Holder than those contained in the Tag Along Notice. In the event that the Proposed Sale Transaction is not consummated within the period required by this Section 16(b) or the Proposed Transferee fails timely to
remit to Holder its respective portion of the sale proceeds, the Proposed Sale Transaction shall be deemed to lapse, and any Transfer of Securities pursuant to such Proposed Sale Transaction shall be in violation of the provisions of this
Section 16(b) unless the Selling Holder sends a new Tag-Along Notice and once again complies with the provisions of Section 16(b) with respect to such Proposed Sale Transaction. 

(vi) Holder’s Tag Along Right set forth in this Section 16(b) shall terminate and be of no further force or effect
following the earlier to occur of (i) an IPO, and (b) the consummation of an Acquisition. 
 17. Representations,
Warranties and Covenants. This Warrant is issued and delivered by the Company and accepted by each Holder on the basis of the following representations, warranties and covenants made by the Company: 

(a) The Company has all necessary authority to issue, execute and deliver this Warrant and to perform its obligations hereunder.
This Warrant has been duly authorized issued, executed and delivered by the Company and is the valid and binding obligation of the Company, enforceable in accordance with its terms. 

(b) The Shares issuable upon the exercise of this Warrant (and the shares of Common Stock issuable upon conversion of the Shares,
if the Class is a series of convertible preferred stock) have been duly authorized and reserved for issuance by the Company out of its authorized and unissued capital stock, and, when issued in accordance with the terms hereof (and, with respect to
and the shares of Common Stock issuable upon conversion of the Shares, if the Class is a series of convertible stock, in accordance with the provisions of the Company’s Articles or Certificate of Incorporation or Organization, as amended and in
effect from time to time (the “Charter”)), will be validly issued, fully paid and non-assessable. 
 (c)
The issuance, execution and delivery of this Warrant do not, and the issuance of the Shares upon the exercise of this Warrant in accordance with the terms hereof will not, (i) violate or contravene the Charter or the Company’s by-laws,
or any law, statute, regulation, rule, judgment or order applicable to the Company, (ii) violate, contravene or result in a breach or default under any contract, agreement or instrument to which the Company is a party or by which the Company or
any of its assets are bound or (iii) require the consent or approval of or the filing of any notice or registration with any person or entity except as may be required under federal and state securities laws. 

(d) At all times, if any, when the Company shall not be subject to the reporting requirements of the Exchange Act, as long as this
Warrant is, or any Shares issued upon exercise of this Warrant or any shares of Common Stock issued upon conversion of such Shares are, outstanding and held by Holder, the Company will at its sole expense provide to the Holder from time to time
with: (i) copies of all notices and other written communications to the holders of outstanding shares of the Class, concurrently with the delivery of such notices and other communications to such holders, (ii) within one hundred twenty
(120) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing; (iii) within forty-five (45) days after the end of
each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements; (iv) not later than December 31 in each year, a copy of the Company’s annual budget for the succeeding year as
approved by the Company’s Board of Directors, and (v) such other business and financial information of or concerning the Company as Holder may reasonably request from time to time. 

18. Amendment. The terms of this Warrant may be amended, modified or waived only with the written consent of the Holder and the
Company. 

  
 -7-

 19. Representations and Covenants of the Holder. This Warrant has been entered into
by the Company in reliance upon the following representations and covenants of the Holder, which by its execution hereof the Holder hereby confirms: 
 (a) Investment Purpose. This Warrant and the Shares (and the shares of Common Stock issuable upon conversion of the Shares, if applicable) will be acquired for investment and not with a view to the
sale or distribution of any part thereof in violation of applicable securities laws, and the Holder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 

(b) Accredited Investor. Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated
under the 1933 Act, as presently in effect. 
 (c) Private Issue. The Holder understands (i) neither the Shares
issuable hereunder nor, if the Class is a series of convertible preferred stock, the shares of Common Stock issuable upon conversion of the Shares, have been registered under the 1933 Act or qualified under applicable state securities laws, on the
ground that the issuance contemplated by this Warrant will be exempt from such registration and qualifications requirements, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this
Section 19. 
 (d) Financial Risk. The Holder has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of its investment in this Warrant and the Shares and has the ability to bear the economic risks of such investment. 
 20. Notices, Transfers, Etc. 
 (a) All notices and other
communications required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed telex or facsimile if sent during normal business
hours of the recipient; if not, then on the next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) the next business day after deposit with a
nationally recognized overnight courier, fee prepaid, specifying next business day delivery, with written confirmation of receipt. All notices and other communications shall be addressed to a party at its address set forth below, or at such other
address as a party may designate to the other party upon ten (10) days advance written notice. 
  

					
	If to Holder:	 	RBS Citizens, N.A.
		 	Global Restructuring Group – SIG
		 	28 State Street, 11th Floor MS1100
		 	Boston, Massachusetts 02109
		 	Attention: Matthew J. Governali
		 	Phone:	  	(617) 994-7232
		 	Fax:	  	(617)
		 	Email:	  	matthew.governali@citizensbank.com
		
	If to the Company:	 	Cybex International, Inc.
		 	10 Trotter Drive
		 	Medway, Massachusetts 02053
		 	Attention: Chief Financial Officer
		 	Phone: (508) 533-4300
		 	Fax:
		 	Email:

 (b) Subject to compliance with applicable federal and state securities laws, this Warrant may be
freely transferred by the Holder with respect to any or all of the Shares purchasable hereunder. Subject to the foregoing, upon surrender of this Warrant to the Company, together with the assignment notice annexed hereto duly executed for transfer
of this Warrant (i) as an entirety by the Holder, the Company shall issue a new warrant of the same tenor and denomination to the assignee, or (ii) with respect to a portion of the Shares purchasable hereunder,

  
 -8-

 
the Company shall issue a new warrant to the assignee, in the same tenor as this Warrant and in such denomination as shall be requested by the Holder hereof, and shall issue to such Holder a new
warrant of like tenor covering the Shares in respect of which this Warrant shall not have been transferred. In connection with any such transfer by Holder, the Company may require the execution and delivery of reasonable and customary investment
representations and a reasonable and customary legal opinion that such transfer is exempt from the registration requirements of the 1933 Act; provided, that no legal opinion shall be required in connection with any transfer by Holder to an
affiliate of Holder, provided that such affiliate transferee is an “accredited investor” as defined in Regulation D promulgated under the 1933 Act; nor shall such affiliate transferee be required to execute and deliver separate investment
representations, but shall be deemed, upon receipt of this Warrant or portion thereof to have made to the Company each of the representations set forth in Section 19 above. 

(c) In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall issue a new warrant of like tenor and
denomination and deliver the same (i) in exchange and substitution for and upon surrender and cancellation of any mutilated Warrant, or (ii) in lieu of any Warrant lost, stolen or destroyed, upon receipt of an affidavit of the Holder and
appropriate indemnification agreement in favor of the Company. 
 21. No Impairment. The Company will not, by amendment
of its Charter or through any reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets, dissolution, liquidation, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
of performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the
Holder. 
 22. Governing Law. The provisions and terms of this Warrant shall be governed by and construed in accordance
with the internal laws of the Commonwealth of Massachusetts, without giving effect to its principles regarding conflicts of laws. 
 23. Successors and Assigns. This Warrant shall be binding upon the Company’s successors and assigns and shall inure to the benefit of the Holder’s successors, legal representatives and
permitted assigns. 
 24. Business Days. If the last or appointed day for the taking of any action required or the
expiration of any rights granted herein shall be a Saturday or Sunday or a legal holiday in Delaware, then such action may be taken or right may be exercised on the next succeeding day which is not a Saturday or Sunday or such a legal holiday.

 25. Restrictive Legends. Each certificate representing shares of the Company’s capital stock received by the
Holder upon exercise of this Warrant shall bear a legend substantially in the following form: 
 “The securities represented
by this certificate have not been registered under the Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such Act or an opinion of
counsel satisfactory to the Company is obtained to the effect that such registration is not required.” 
 The foregoing
legend shall be removed from the certificate(s) at the request of the holder thereof, at such time as they become eligible for resale pursuant to Rule 144 under the Act. 
 26. Attorneys’ Fees. In any action or proceeding between the parties under or respecting this Warrant, the prevailing party in such action or proceeding shall be entitled to collect
from the other party all costs and expenses incurred in the investigation and prosecution of such action or proceeding, including, without limitation, reasonable attorneys’ fees. 

[Remainder of page left blank intentionally; signature page follows] 

  
 -9-

 IN WITNESS WHEREOF, the Company has executed this Stock Purchase Warrant by its duly
authorized officer as of the date first above written. 
  

			
	CYBEX INTERNATIONAL, INC.
		
	By:	 	 /s/ Arthur W. Hicks, Jr.

	Name:	 	Arthur W. Hicks, Jr.
	Title:	 	President

  

			
	ACCEPTED AND AGREED TO:
	
	RBS CITIZENS, N.A.
		
	By:	 	 /s/ Thomas Schmidt

	Name:	 	Thomas Schmidt
	Title:	 	Vice President

  
 -10-

 Subscription 

 

			
	To:	 	  

		
	Date:	 	  

 The undersigned hereby subscribes for
                     shares of the Shares covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the undersigned
or as otherwise indicated below: 
  

	
	  

	Signature
	
	  

	Name for Registration
	
	  

	Mailing Address

 Net Issue Election Notice 

 

									
	To:	 	  
	 		 	Date:	 	  

 The undersigned hereby elects under Section 4 to surrender the right to purchase shares of the Shares
pursuant to this Warrant. The certificate(s) for such shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below: 

 

	
	  

	Signature
	
	  

	Name for Registration
	
	  

	Mailing Address

 Assignment 
 For value received
                                         
                                        hereby sells,
assigns and transfers unto 
   

 
  
  

 
 [Please print or typewrite name and address of
Assignee] 
  
  
 the within Warrant, and does hereby irrevocably constitute and appoint
                                         
                    its attorney to transfer the within Warrant on the books of the within named Company with full power of substitution on the premises.

  

			
	Dated:	 	  

	
	  

	Signature
	
	  

	Name for Registration

 In the Presence of:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]